Celgene and Agios enter new deal focused on metabolic immuno-oncology
Building on a successful relationship that began in 2010, Celgene Corp. and Agios Pharmaceuticals Inc. entered into a new collaboration, this time focused on metabolic immuno-oncology, which involves altering the metabolic state of immune cells to enhance immune response to cancer.
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.